Palvella Therapeutics, Inc.
Financials
Valuation Metrics
Palvella Therapeutics, Inc.'s Market Cap is $2.21B. At end of 2025 it was $1.18B. Ranked #1951 of 3,121 in US market (top 63%), #737 of 1,463 on NASDAQ (top 50%), #126 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 47%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.21B | US#1,951/3,121 Sec#126/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-62M | US—/3,121 Sec—/266 |
| Total Assets | $254M | US#2,953/3,121 Sec#226/266 |
| Net Assets | $217M | US#2,663/3,121 Sec#188/266 |
| Employees | 29 | US#2,753/3,121 Sec#220/266 |
| Value | ||
| P/B | 10.21x | US#2,624/3,121 Sec#197/266 |
| FCF Yield | -1.65% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -28.45% | US#2,559/3,121 Sec#111/266 |
| ROA | -24.34% | US#2,846/3,121 Sec#141/266 |
| Financial Health | ||
| Debt Ratio | 16.87% | US#194/3,121 Sec#72/266 |
| Total Debt | $535000.00 | US#3,001/3,121 Sec#254/266 |
| FCF | $-37M | US#2,488/3,121 Sec#104/266 |
| Cash | $188M | US#1,785/3,121 Sec#114/266 |
| Current Ratio | 21.18x | US#114/3,121 Sec#23/266 |
| Performance | ||
| 1Y Return | 172.79% | US#85/3,121 Sec#33/266 |
| 1M Return | 2.59% | US#666/3,121 Sec#67/266 |
| From 52W High | -4.37% | US#257/3,121 Sec#21/266 |
| 1Y MDD | -31.11% | US#1,500/3,121 Sec#95/266 |
| Trading | ||
| Volume | 143,717 shares | US#2,803/3,121 Sec#258/266 |
| Trading Value | $22M | US#1,808/3,121 Sec#141/266 |
| Per Share | ||
| EPS | $-4.30 | US—/3,121 Sec—/266 |
| BPS | $15.12 | US#1,523/3,121 Sec#48/266 |
Company Info
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.